Dr. Reddy's and Takeda Partner for Qdenga Dengue Vaccine Distribution in India

Dr. Reddy's Laboratories has secured an exclusive distribution agreement with Japanese drugmaker Takeda Pharmaceutical Company to market Qdenga, India's first approved dengue vaccine, across the country's private healthcare market. Subject to completion of local regulatory procedures, the live-attenuated tetravalent immunization is anticipated to become commercially available for pediatric and adult populations in the first half of 2027.

The Central Drugs Standard Control Organization granted marketing authorisation for Qdenga in July 2026, clearing the vaccine for individuals aged 4 to 60 years. While Dr. Reddy's will oversee private-market distribution, disease awareness campaigns, and healthcare professional engagement, Takeda retains legal ownership, medical oversight, and future rights for the public immunisation market.

Qdenga, internationally recognized as TAK-003, is engineered as a live-attenuated tetravalent vaccine designed to deliver immune protection against all four circulating dengue virus serotypes, designated DENV-1 through DENV-4. The formulation uses a DENV-2 backbone combined with structural proteins derived from the remaining three serotypes to elicit a broad immunological response across diverse geographical strains.

The immunization protocol requires a two-dose regimen administered at an interval of three months between injections. According to corporate disclosures from Takeda, the vaccine can be administered regardless of a patient's prior dengue infection history, which removes the clinical requirement for pre-vaccination serological screening before administration.

Takeda's global clinical development program encompassed more than 60,000 participants across eight dengue-endemic countries. The manufacturer's seven-year Phase 3 TIDES clinical evaluation reported sustained overall efficacy across all four viral serotypes through seven years of monitoring, though these findings reflect trial data rather than individual immunity guarantees.

Dengue has emerged as one of the fastest-growing vector-borne viral infections globally, creating a substantial public health challenge across tropical and subtropical regions. Data cited by Dr. Reddy's indicates that reported dengue cases in India have surged eleven-fold over the past two decades, underscoring the expanding domestic footprint of the disease.

A nationwide surveillance study conducted by the Indian Council of Medical Research's Virus Research and Diagnostic Laboratory revealed that all four dengue serotypes circulate concurrently across multiple regions in India. Furthermore, the surveillance findings showed that 1 in 14 patients evaluated presented with simultaneous infections involving multiple viral serotypes.

Globally, Qdenga has received regulatory approvals in 43 countries since 2022, with more than 32 million doses distributed across public and private immunisation programs in regions including Southeast Asia, Latin America, and Europe. The World Health Organization has included the vaccine in its prequalified list and recommended its deployment without pre-vaccination screening in high-endemic settings.

The distribution pact establishes a dual-market operational structure between the two pharmaceutical entities. Dr. Reddy's will operate exclusively within the private vaccination sector, leveraging its established domestic footprint as one of the country's major vaccine suppliers to drive commercial availability and professional outreach.

M.V. Ramana, CEO of Global Generics at Dr. Reddy's Laboratories, noted the commercial significance of the partnership. As the second-largest vaccine player in India, Ramana stated that introducing the country's first approved dengue vaccine represents an important milestone for the domestic healthcare landscape and offers a concrete tool to address the national disease burden.

Takeda maintains legal ownership of the brand and retains full control over future public-sector distribution strategies. Dr. Mahender Nayak, Head of Intercontinental Markets for Takeda's International Business Unit, highlighted that the private-market alliance will ensure timely access for eligible individuals once commercial supply commences in 2027.

Nayak also pointed to broader policy discussions surrounding public immunisation integration, noting that Takeda welcomes recent recommendations from the Parliamentary Committee on Health to consider incorporating the dengue vaccine into the Universal Immunization Program as a long-term public health objective.